EUVIMEDEUVIMED entdecken
Crossref

Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries

Archit S Pandharipande, Silky Jain, Anuj Singh, Shruti Verma, Eby P Baby, Hari Gaire, Sudipto Bhattacharya, Aditi Tulsiyan, Savitri Singh, Nita Radhakrishnan

International Journal of Hematology · 2026

DOI: 10.1007/s12185-025-04075-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2026. Verfasst von Archit S Pandharipande und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, 201303, India. Hauptthemen laut MEDLINE: Hemophilia A, Hemophilia B, Factor VIII, Hemarthrosis. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The real-world data on treatment and outcome of hemophilia patients using extended half-life products in developing countries remain scarce. This is largely due to delayed diagnosis, poor joint outcomes, increased morbidity, and limited access to prophylaxis and newer products for treatment and prevention. AIM: To analyze the response to extended half-life factor (EHL) prophylaxis in patients with severe hemophilia A and B with advanced arthropathy. METHODS: Patients with severe hemophilia A and B who received EHL factor concentrates for prophylaxis at our center were included in this analysis. Data collected included bleed frequency, joint involvement, annualized bleed rate (ABR), number of hospital visits, and Hemophilia Joint Health Score (HJHS) prior to prophylaxis. Breakthrough bleeds while on prophylaxis were also recorded. RESULTS: A total of 31 patients were started on EHL prophylaxis and followed up for a period ranging from 4 to 91 weeks. A reduction in the bleeding rate was noticed in all with significant reversal of target joints. Additionally, patients remained bleed-free during rehabilitation following joint surgery as well as psoas bleed-related compression neuropathy. CONCLUSION: EHL prophylaxis appears to be an effective strategy even for patients with baseline target joints with significant arthropathy, thus reducing the extent of disability in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemophilia BFactor VIIIHemarthrosisHumansDeveloping CountriesMaleAdultHalf-LifeHemorrhageAdolescentMiddle AgedFemaleYoung AdultTreatment OutcomeChild

Stichwörter der Autor:innen

EHLExtended half-life factor prophylaxisHemophilia A and BProphylaxis

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, 201303, India.
  • Department of Pathology, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, 201303, India.
  • Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, 201303, India. nitaradhakrishnan@yahoo.com.

Zitieren

APA

Pandharipande, A. S., Jain, S., Singh, A., Verma, S., Baby, E. P., Gaire, H., Bhattacharya, S., Tulsiyan, A., Singh, S., & Radhakrishnan, N. (2026). Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries. International Journal of Hematology. https://doi.org/10.1007/s12185-025-04075-0

Vancouver

Pandharipande AS, Jain S, Singh A, Verma S, Baby EP, Gaire H, et al. Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries. International Journal of Hematology. 2026. doi:10.1007/s12185-025-04075-0

BibTeX
@article{Pandharipande2026,
  author = {Pandharipande, Archit S and Jain, Silky and Singh, Anuj and Verma, Shruti and Baby, Eby P and Gaire, Hari and Bhattacharya, Sudipto and Tulsiyan, Aditi and Singh, Savitri and Radhakrishnan, Nita},
  title = {Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries},
  journal = {International Journal of Hematology},
  year = {2026},
  doi = {10.1007/s12185-025-04075-0}
}
Kostenlos starten →